What Happened?
San Diego, CA-based Turning Point Therapeutics Appointed Joel Muller as Associate Director, Accounting
Date of management change: March 08, 2022
San Diego, CA-based Turning Point Therapeutics Appointed Joel Muller as Associate Director, Accounting
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Joel Muller is Associate Director, Accounting at Turning Point Therapeutics. Previously, Joel held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Burke John, Baker Travis, Dias Karl, Sabourin Paul, Batra Rohit, Shutt Arden, Shephard Patricia, Payson Linda, Mason Chris, MacIntire-Pandolph Kristen, McLeod Dale
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.